Low-cost steroid reduces death rate of COVID-19
Print Edition
The World Health Organization said it was moving to update its guidelines on treating people stricken with COVID-19 to reflect results of a clinical trial that showed a low-cost, common steroid drug can help save critically ill patients.
Trial results announced on Tuesday by researchers in Britain showed dexamethasone, used since the 1960s to reduce inflammation in diseases such as arthritis, can effectively reduce death rates among the most severely ill COVID-19 patients admitted to hospital.
According to preliminary findings shared with WHO, for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.
However, the benefit was only seen in patients seriously ill with COVID-19 and was not observed in patients with milder disease.
The preliminary results, which have not been peer-reviewed yet, suggest the drug should immediately become standard care in patients with severe cases of the disease, according to researchers who led the trials.
鈥淭his is the first treatment shown to reduce mortality in patients with COVID-19 requiring oxygen or ventilator support,鈥 WHO Director-General Tedros Adhanom Ghebreyesus said in a statement late on Tuesday.
The agency said it was looking forward to the full data analysis of the study in coming days.
鈥淲HO will coordinate a meta-analysis to increase our overall understanding of this intervention. WHO clinical guidance will be updated to reflect how and when the drug should be used in COVID-19,鈥 the agency added.
鈥淭his is a (trial) result showing if patients who have COVID-19 and are on ventilators or oxygen receive dexamethasone, it will save lives and will do so at a remarkably low cost,鈥 said Martin Landray, an Oxford University professor co-leading the clinical trial.
鈥淔or less than 50 pounds (US$63), you can treat eight patients and save lives.鈥
His co-lead investigator, Peter Horby, called dexamethasone 鈥渁 major breakthrough.鈥
They said they would work to publish the full details of the trial as soon as possible, and many scientists said they hope to be able to review the evidence for themselves soon.
The WHO鈥檚 clinical guidance for treating patients infected with the disease is aimed at doctors and other medical professionals and intends to use the latest data to inform clinicians on how best to tackle all phases of the disease 鈥 from screening all the way through to discharge.
But South Korea鈥檚 top health official cautioned about the use of the drug for COVID-19 patients.
鈥淚t has already long been used in South Korean hospitals to treat patients with different inflammation,鈥 said Jeong Eun-kyeong, head of South Korea鈥檚 Centers for Disease Control and Prevention.
鈥淪ome experts have warned of the drug not only reducing the inflammatory response in patients, but also the immune system and may trigger side-effects. We are discussing the use of it for COVID-19 patients.鈥
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
